5. Januar 2024 – Blenrep is a medicine for treating multiple myeloma (a cancer of the bone marrow). It was authorised for adults who had received at least four previous treatments and whose disease did not respond to certain other types of treatment and had worsened since the last treatment. The European Medicines Agency’s (EMA) Human Medicines Committee (CHMP) has confirmed its initial recommendation to not renew the conditional marketing authorisation for Blenrep (belantamab mafodotin) because recent data did not confirm its effectiveness. The benefits of Blenrep are therefore considered to no longer outweigh its risks.

For more information, see here.